Having received accelerated approval from US Food and Drug Administration (FDA) in January this year for their Alzheimer’s disease drug Leqembi (lecanemab), Japan’s Eisai (TYO: 4523) and US biotech Biogen (Nasdaq: BIIB) are now awaiting authorizations in the important markets of the European Union and Japan to solidify the drug’s position as the top-selling drug for Alzheimer's in the upcoming years.
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9 billion between 2023 and 2028, according to data and analytics company GlobalData.
The FDA decision on Leqembi was based on data from a Phase II clinical trial named Athena AD. The results of the trial showed that treatment led to a significant reduction in the amount of amyloid beta plaques in the brain and demonstrated a statistically significant reduction in cognitive decline in patients treated with Leqembi compared to those who received a placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze